期刊文献+

脾酪氨酸激酶对恶性肿瘤的影响及其抑制剂的临床应用

下载PDF
导出
摘要 恶性肿瘤是具有较大异型性的组织异常新生物,通常伴有侵袭和转移的特性,传统肿瘤减灭术配合放化疗易使其产生耐药性,导致肿瘤的复发、转移,患者预后差、生活质量低、死亡率高。肿瘤的发生发展与多种信号通路相关,对其中关键信号通路的研究有利于开发靶向药物,为癌症治疗提供新思路。
出处 《长治医学院学报》 2024年第1期77-80,共4页 Journal of Changzhi Medical College
基金 省级大学生创新创业训练项目(20220847) 山西省卫生健康委科研项目(2019135)。
  • 相关文献

参考文献5

二级参考文献53

  • 1Coopman PJ,Do MT,Barth M,et al. The Syk tyrosine kinase sup- presses malignant growth of human breast cancer cells[ J ]. Nature, 2000,406 ( 8 ) : 742-747.
  • 2Zhao YC, Ni X J, Li Y, et al. Peritumoral lymphangiogenesis in- duced by vascular endothelial growth factor C and D promotes lymph node metastasis in breast cancer patients [J]. World J Surg Onco1,2012,20 (10) : 165.
  • 3Wu Qw, She HQ, Liang J, et al. Expression and clinical signifi- cance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer [ J]. BMC Cancer,2012,27 ( 12 ) :47.
  • 4Abtahian F, Guerriero A, Sebzda E, et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk [ J ]. Science,2003,299 (5604) :247-251.
  • 5Bogusz AM, Baxter RH, Currie T, et al. Quantitative immunoflu- orescence reveals the signature of active B-cell receptor signal- ing in diffuse large B-cell lymphoma [J]. Clin Cancer Res, 2012, 18(22): 6122-6135.
  • 6Chen L, Monti S, Juszczynski P, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholester- ol biosynthesis in diffuse large B cell lymphomas [J]. Cancer Cell, 2013, 23(6): 826-838.
  • 7Suljagic M, Longo PG, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Et- TCL1 transgenic mouse model of CLL by blocking antigen- dependent B-cell receptor signaling [J]. Blood, 2010, 116 (23): 4894-4905.
  • 8Ffiedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia [ J ]. Blood, 2010, 115( 13): 2578-2585.
  • 9Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine ki- nase inhibitor, in chronic lymphocytic leukemia [J]. Blood, 2015, 125( 15):2336-2343.
  • 10Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI- 32765[J]. Blood, 2011, 117(23): 6287-6296.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部